【摘要翻译】国外研究NMP22进展的两篇报告
这个帖子发布于 20 年零 255 天前，其中的信息可能已发生改变或有所发展。
第一篇,侧重与研究NMP22对临床诊断泌尿系肿瘤的重要性
【题目】 尿核基质蛋白22(NMP22)作为泌尿系上皮肿瘤标志物的临床研究
【作者】Takeuchi Y, Sawada Y, Yabuki D, Masuda E, Satou D, Kuroda K, Tajima M, Sawamura Y, Matsushima M.
【杂志】Aktuelle Urologie. 2003 Jul;34(4):265-6
【摘要】The prognosis of urinary epithelial cancer is still poor, and early detection of this cancer is strongly desirable. The sensitivity of conventional urinary cytology is not satisfactory enough. It is hoped that a specific tumor marker will be established. In recent years, it has been reported that urine NMP 22 is very useful and that urine BFP is also relatively useful. We have now determined urine NMP22 and BFP and studied their clinical usefulness as a tumor marker. Using patients diagnosed with histologically confirmed urinary epithelial cancer as the subjects, we retrospectively studied the usefulness of NMP 22, BFP and cytology mainly with regard to the sensitivity (positivity rate), and also in relation to atypia, degree of infiltration and clinical course
(CHN)泌尿系上皮肿瘤的预后仍然很差,故早期发现肿瘤值得期待 ,常规的尿细胞学检查的敏感度并不能让人满意,研究人员希望能发现一种新的确切的肿瘤标志物.最近几年关于NMP22及尿碱性胎儿蛋白(BFP)对膀胱肿瘤是有意义的报告屡见不鲜.我们分离出尿NMP22 和 BFP 并研究它们作为肿瘤标志物的临床意义.我们已组织学上证实为泌尿上皮肿瘤的病例为研究对象,回顾性研究了NMP22,BFP和尿细胞学检查对于泌尿上皮肿瘤诊断的敏感性及肿瘤的不典型增生,浸润程度和临床病程的价值.
【结论】Our findings suggest that urine NMP22 is highly specific for urinary epithelial cancer and is useful cancer and is more useful for the detection of vesical cancer and observation s onthe clinical course compared withurinary cytology
(CHN)我们的研究结果表明尿NMP22对于泌尿上皮肿瘤的高度的特异性,对于发现膀胱肿瘤及观测临床病程,与尿细胞学检查相比较,更为有效.
第二篇,侧重于分析NMP22对于低分化膀胱肿瘤的意义
【题目】The clinical efficacy of Bladder Chek NMP22 in urothelial cancer
膀胱NMP22(核基质蛋白22)检查在泌尿道上皮肿瘤的临床有效性
【作者】Yokoyama T, Sekigawa R, Hayashi T, Horita S, Kanamuro T, Nonami Y, Sawada T, Nishikawa T, Kobayashi M, Yamaguchi Y, Ishida H, Goya N, Nakazawa H, Toma H.
【杂志】Rinsho Byori. 2004 Mar;52(3):199-203
【摘要】The purpose of this study is to investigate the clinical efficacy of a quick test for NMP22 (Nuclear Matrix Protein 22), Bladder Chek NMP22, as a screening test for urothelial cancers. The subjects include 51 cases(43 cases with pathologically confirmed bladder cancer, and 8 cases with upper urothelial cancer). Bladder Chek NMP22 revealed false positive in the urine with more than 1 x 10(5)/microliter of erythrocytes and 1 x 10(3)/microliter of white blood cells. Thus, showing that Bladder Chek NMP22 was not relatively affected by the contaminated erythrocytes and white blood cells, compared with other conventional methods to detect urinary malignant disease. In 51 cases diagnosed of having pathologically urothelial cancers, the sensitivity of Bladder Chek NMP22 was 56.8%. Bladder Chek NMP22 demonstrated more excellent sensitivity than the other methods. The positivity of Grade3 patients was 68.4%, 68.4% and 63.2% by Bladder Chek NMP22, NMP22 ELISA and urinary cytology. In contrast, the positivity rate for the patients with Grade1 stage was 58.3%, 33.3% and 8.3%. There is no significance of positivity rate between each examination in patients with high grade cancer. However Bladder Chek NMP22 demonstrated the higher positivity in patients with low grade cancer. Bladder Chek NMP22 test could be an easy and confidential method to detect urothelial cancers, especially with low grade, as a screening examination.
这项研究的目的是调查NMP22(核基质蛋白22)的快速检查的临床有效性,膀胱NMP22(核基质蛋白22)检查可作为泌尿到道肿瘤的筛选实验.研究对象包括51例患者(其中有43例病理证实为膀胱癌,8例为上尿路肿瘤).NMP22检查显示了含有超过1 x 10(5)/毫升红细胞和1 x 10(3)/毫升白细胞尿液的假阳性.结果表明和其他传统的检测泌尿系统肿瘤方法相比,NMP22检查是相对不受污染的红细胞和白细胞的影响.在51例病理确诊为膀胱癌的患者中,NMP22检查的敏感度为56.8%.NMP检查和其他诊断方法相比,显示了极佳的敏感性.膀胱癌G3的患者,膀胱 NMP22检查,NMP22酶联免疫吸附实验及尿细胞学检查的诊断敏感度分别为68.4%, 68.4% 和 63.2% .与之相对比的是,膀胱癌G1的诊断阳性率分被为58.3%, 33.3% 和 8.3%.在高分化的膀胱肿瘤患者中三种检查的阳性率无明显差别,而在在低分化的的膀胱肿瘤中,NMP检查却有更高的阳性率,NMP检查可能对于泌尿系肿瘤,特别是低分化肿瘤,是一种简易而有效的检测方法.
附全文
尿核基质蛋白22(NMP22)作为泌尿系上皮肿瘤标志物的临床研究
【题目】 尿核基质蛋白22(NMP22)作为泌尿系上皮肿瘤标志物的临床研究
【作者】Takeuchi Y, Sawada Y, Yabuki D, Masuda E, Satou D, Kuroda K, Tajima M, Sawamura Y, Matsushima M.
【杂志】Aktuelle Urologie. 2003 Jul;34(4):265-6
【摘要】The prognosis of urinary epithelial cancer is still poor, and early detection of this cancer is strongly desirable. The sensitivity of conventional urinary cytology is not satisfactory enough. It is hoped that a specific tumor marker will be established. In recent years, it has been reported that urine NMP 22 is very useful and that urine BFP is also relatively useful. We have now determined urine NMP22 and BFP and studied their clinical usefulness as a tumor marker. Using patients diagnosed with histologically confirmed urinary epithelial cancer as the subjects, we retrospectively studied the usefulness of NMP 22, BFP and cytology mainly with regard to the sensitivity (positivity rate), and also in relation to atypia, degree of infiltration and clinical course
(CHN)泌尿系上皮肿瘤的预后仍然很差,故早期发现肿瘤值得期待 ,常规的尿细胞学检查的敏感度并不能让人满意,研究人员希望能发现一种新的确切的肿瘤标志物.最近几年关于NMP22及尿碱性胎儿蛋白(BFP)对膀胱肿瘤是有意义的报告屡见不鲜.我们分离出尿NMP22 和 BFP 并研究它们作为肿瘤标志物的临床意义.我们已组织学上证实为泌尿上皮肿瘤的病例为研究对象,回顾性研究了NMP22,BFP和尿细胞学检查对于泌尿上皮肿瘤诊断的敏感性及肿瘤的不典型增生,浸润程度和临床病程的价值.
【结论】Our findings suggest that urine NMP22 is highly specific for urinary epithelial cancer and is useful cancer and is more useful for the detection of vesical cancer and observation s onthe clinical course compared withurinary cytology
(CHN)我们的研究结果表明尿NMP22对于泌尿上皮肿瘤的高度的特异性,对于发现膀胱肿瘤及观测临床病程,与尿细胞学检查相比较,更为有效.
第二篇,侧重于分析NMP22对于低分化膀胱肿瘤的意义
【题目】The clinical efficacy of Bladder Chek NMP22 in urothelial cancer
膀胱NMP22(核基质蛋白22)检查在泌尿道上皮肿瘤的临床有效性
【作者】Yokoyama T, Sekigawa R, Hayashi T, Horita S, Kanamuro T, Nonami Y, Sawada T, Nishikawa T, Kobayashi M, Yamaguchi Y, Ishida H, Goya N, Nakazawa H, Toma H.
【杂志】Rinsho Byori. 2004 Mar;52(3):199-203
【摘要】The purpose of this study is to investigate the clinical efficacy of a quick test for NMP22 (Nuclear Matrix Protein 22), Bladder Chek NMP22, as a screening test for urothelial cancers. The subjects include 51 cases(43 cases with pathologically confirmed bladder cancer, and 8 cases with upper urothelial cancer). Bladder Chek NMP22 revealed false positive in the urine with more than 1 x 10(5)/microliter of erythrocytes and 1 x 10(3)/microliter of white blood cells. Thus, showing that Bladder Chek NMP22 was not relatively affected by the contaminated erythrocytes and white blood cells, compared with other conventional methods to detect urinary malignant disease. In 51 cases diagnosed of having pathologically urothelial cancers, the sensitivity of Bladder Chek NMP22 was 56.8%. Bladder Chek NMP22 demonstrated more excellent sensitivity than the other methods. The positivity of Grade3 patients was 68.4%, 68.4% and 63.2% by Bladder Chek NMP22, NMP22 ELISA and urinary cytology. In contrast, the positivity rate for the patients with Grade1 stage was 58.3%, 33.3% and 8.3%. There is no significance of positivity rate between each examination in patients with high grade cancer. However Bladder Chek NMP22 demonstrated the higher positivity in patients with low grade cancer. Bladder Chek NMP22 test could be an easy and confidential method to detect urothelial cancers, especially with low grade, as a screening examination.
这项研究的目的是调查NMP22(核基质蛋白22)的快速检查的临床有效性,膀胱NMP22(核基质蛋白22)检查可作为泌尿到道肿瘤的筛选实验.研究对象包括51例患者(其中有43例病理证实为膀胱癌,8例为上尿路肿瘤).NMP22检查显示了含有超过1 x 10(5)/毫升红细胞和1 x 10(3)/毫升白细胞尿液的假阳性.结果表明和其他传统的检测泌尿系统肿瘤方法相比,NMP22检查是相对不受污染的红细胞和白细胞的影响.在51例病理确诊为膀胱癌的患者中,NMP22检查的敏感度为56.8%.NMP检查和其他诊断方法相比,显示了极佳的敏感性.膀胱癌G3的患者,膀胱 NMP22检查,NMP22酶联免疫吸附实验及尿细胞学检查的诊断敏感度分别为68.4%, 68.4% 和 63.2% .与之相对比的是,膀胱癌G1的诊断阳性率分被为58.3%, 33.3% 和 8.3%.在高分化的膀胱肿瘤患者中三种检查的阳性率无明显差别,而在在低分化的的膀胱肿瘤中,NMP检查却有更高的阳性率,NMP检查可能对于泌尿系肿瘤,特别是低分化肿瘤,是一种简易而有效的检测方法.
附全文
尿核基质蛋白22(NMP22)作为泌尿系上皮肿瘤标志物的临床研究
回复1 点赞
